Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SNDX

SNDX - Syndax Pharmaceuticals Inc Stock Price, Fair Value and News

$20.56-0.75 (-3.52%)
Market Closed

54/100

SNDX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

54/100

SNDX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$22.15

Target 3M

$20.72

Target 6M

$21.18

SNDX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SNDX Price Action

Last 7 days

0.2%

Last 30 days

-2.4%

Last 90 days

53.6%

Trailing 12 Months

43.2%

SNDX RSI Chart

SNDX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SNDX Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-5.74

Price/Sales (Trailing)

16.02

Price/Free Cashflow

-5.75

SNDX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$22.15

Target 3M

$20.72

Target 6M

$21.18

SNDX Fundamentals

SNDX Revenue

Revenue (TTM)

111.6M

SNDX Earnings

Earnings (TTM)

-311.6M

Earnings Growth (Yr)

27.83%

Earnings Growth (Qtr)

15.49%

SNDX Profitability

Return on Equity

-269.93%

Return on Assets

-56.47%

Free Cashflow Yield

-17.4%

SNDX Investor Care

Shares Dilution (1Y)

1.88%

Diluted EPS (TTM)

-3.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202550.9M78.2M111.6M0
20240101.0M62.4M23.7M
20211.5M1.5M13.5M139.7M
20201.5M1.5M1.5M1.5M
20191.5M1.5M1.5M1.5M
20182.2M2.3M2.3M1.5M
20171.2M1.2M1.2M2.1M
2016775.3K923.5K1.1M1.2M
2015000627.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Syndax Pharmaceuticals Inc

SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEsyndax.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES107

Syndax Pharmaceuticals Inc Frequently Asked Questions

SNDX is the stock ticker symbol of Syndax Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Syndax Pharmaceuticals Inc is 1.79 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SNDX's fair value in chart for subscribers.

The fair value guage provides a quick view whether SNDX is over valued or under valued. Whether Syndax Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Syndax Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNDX.

As of Wed Jan 28 2026, SNDX's PE ratio (Price to Earnings) is -5.74 and Price to Sales (PS) ratio is 16.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNDX PE ratio will change depending on the future growth rate expectations of investors.